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Abstract
Background and Objectives: There is a critical need for effective interventions to support quality of life for persons living
with dementia and their caregivers. Growing evidence supports nonpharmacologic programs that provide care management, disease education, skills training, and support. This cost–benefit analysis examined whether the Care of Persons with
Dementia in their Environments (COPE) program achieves cost savings when incorporated into Connecticut’s home- and
community-based services (HCBS), which are state- and Medicaid-funded.
Research Design and Methods: Findings are based on a pragmatic trial where persons living with dementia and their caregiver dyads were randomly assigned to COPE with HCBS, or HCBS alone. Cost measures included those relevant to HCBS
decision makers: intervention delivery, health care utilization, caregiver time, formal care, and social services. Data sources
included care management records and caregiver report.
Results: Per-dyad mean cost savings at 12 months were $2 354 for those who received COPE with a mean difference-indifference of −$6 667 versus HCBS alone (95% CI: −$15 473, $2 734; not statistically significant). COPE costs would
consume 5.6%–11.3% of Connecticut’s HCBS annual spending limit, and HCBS cost-sharing requirements align with
participants’ willingness to pay for COPE.
Discussion and Implications: COPE represents a potentially cost-saving dementia care service that could be financed
through existing Connecticut HCBS. HCBS programs represent an important, sustainable payment model for delivering
nonpharmacological dementia interventions such as COPE.

© The Author(s) 2021. Published by Oxford University Press on behalf of The Gerontological Society of America.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits
unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
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Background and Objectives
In the United States, 5.8 million people are living with
Alzheimer’s disease and related dementias (ADRDs), and
two-thirds of $290 billion annual dementia-related health
care costs are borne by Medicare and Medicaid (1). Added
to this cost is the time value of caregiving provided by
family/friends to persons living with dementia (2). Due to
the lack of interventions to slow, halt, or reverse dementia’s
pathology coupled with the aging of America, both direct
and indirect dementia-related costs are expected to increase
in the foreseeable future.
Given these trends, there is a critical need for effective
interventions to support quality of life for persons living
with dementia and their caregivers. Growing evidence
supports nonpharmacologic programs that provide care
management (CM), disease education, skills training, and
support (3–5). Most evidence to date has been derived from
randomized control trials, which may not be reflective of
everyday life, representing a need to further test their effectiveness in a real-world home- and community-based
service (HCBS) setting (6–10).
This study presents a cost–benefit analysis (CBA)
conducted alongside the Care of Persons with Dementia
in their Environments (COPE) program in Connecticut
(“COPE-CT”). COPE-CT is the first known pragmatic and
randomized trial to determine the effectiveness of an evidence-based dementia care intervention into a state HCBS
program (11). HCBS are offered in more than 40 states
to support the care of the most vulnerable members of
the population (12). The Connecticut HCBS program for
older adults, formally known as the Connecticut Home
Care Program for Elders (CHCPE), is state- and Medicaidfunded and provides different categories of benefits
based on functional status and income (13). The CHCPE
categories also have different monthly spending limits
and participant cost-sharing requirements (13). CHCPE
Categories 1 and 2 are state-funded and Category 3 is
Medicaid waiver-funded. Categories 1 and 2 participants
have 9% cost sharing on the total cost of benefits provided,
while Category 3 has no cost-sharing requirements. Of
the 16 000 CHCPE beneficiaries served annually, approximately 25%–30% have an ADRD diagnosis (11).

The main goal of our CBA was to determine if COPE
delivered with HCBS resulted in cost savings compared
to HCBS alone (usual care). Secondarily, we sought to
examine a potential payment model whereby COPE is
a covered service under Connecticut HCBS, based on its
fit within monthly spending limits. Finally, we examined
whether caregivers’ willingness to pay (WTP) for COPE
falls within CHCPE cost-sharing levels.

Research Design and Methods
Description of the Pragmatic Trial
The COPE-CT pragmatic trial has been described elsewhere
(11,14). Briefly, persons living with dementia and caregiver
dyads were enrolled after eligibility screening and informed
consent (14). To be eligible, the person living with dementia
had to be enrolled in CHCPE and receive a monthly home
care plan from Connecticut Community Care (CCC, a CM
provider), have a diagnosis of dementia or ≥4 errors on the
Mental Status Questionnaire (indicative of moderate cognitive impairment), and speak English. Caregivers had to be
≥21 years old, willing and able to participate in the study,
plan to live in the area for 12 months, and speak English.
Consistent with a pragmatic approach, CCC was directly involved in planning and implementing the study.
CCC is Connecticut’s largest CM organization supporting
CHCPE (14). CCC’s care managers annually evaluate the
person living with dementia’s needs and create personalized
HCBS care plans. CCC care managers identified CHCPE
clients and their caregiver dyads who were potential study
candidates by examining their client lists and during routine phone calls, explaining study features to provisionally eligible clients and/or their caregivers. Interested
dyads were referred to the research team at the University
of Connecticut Center on Aging who conducted final
screening and consent.
Dyads randomized to the COPE group received up to
10 in-home sessions delivered by an occupational therapist (OT), as well as 1 in-home visit and 1 telephone call
by an advanced practice nurse (APN) (14). During the OT
sessions, the person living with dementia was assessed for
functional limitations and environmental stressors, and the
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Translational Significance: This study presents a robust economic analysis of a dementia support program,
Care of Persons with Dementia in their Environments (COPE), tested in a pragmatic trial as a service embedded in the Connecticut home- and community-based services (HCBS) program. The COPE program resulted in net cost savings in several direct health care cost categories and can be delivered through the existing
Connecticut HCBS program. We also present a potential payment model for this program which could be
adapted to other states’ HCBS programs.
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Cost Study Approach
We estimated the net cost of delivering COPE relative to
HCBS usual care based on cost data obtained during the
trial and assessed whether the net financial benefit of COPE
was ≥$0. The cost analysis was conducted from a HCBS
decision-maker perspective and included 130 dyads in the
COPE plus HCBS group and 120 dyads in HCBS only for
whom CCC data were available, representing 86% of the
main study sample (consort chart in Supplementary Figure
A1). Among dyads randomized to COPE, caregivers in the
cost sample compared to the noncost sample were more
likely to be female and daughters of the person living with
dementia (p = .01). Because the noncost study sample for the

COPE group was small (15 participants), these differences
could be due to chance. There were no differences between
participants in the cost study and those in the noncost
study for the usual care group (Supplementary Table A1).
Costs were measured for both study groups and included direct and indirect costs. We measured the direct
cost of delivering COPE or usual care (staff time costs,
travel, and supplies), health care services, and formal care
and social services. We also measured indirect costs as the
dollar value of caregivers’ time spent actively caring for or
supervising the person living with dementia. Although the
value of caregiving is a societal cost and not a direct cost
to HCBS funders (16), we included it in the analysis due
to its relevance for dementia. We multiplied all time-based
activity by applicable wage rates.
All costs are presented in $US 2019 (17). Costs from
1 year prior to randomization (“baseline”) were compared
to the year postrandomization (“12 months”) using a
difference-in-difference (DID) approach. Though the intervention is delivered over 4 months, we used a 1-year
pre-/postperiod time horizon to increase the relevance of
findings to HCBS decision makers.

Delivery of Intervention or Usual Care
Control Costs
We captured the COPE and usual care delivery cost using
an investigator-developed template (18,19). Additional resources required for delivering COPE included staff training
and supervision (consisting of case presentation debriefings
with a seasoned OT to ensure treatment fidelity), OT/APN
time with clients and preparing to meet with clients, travel
time and mileage (reimbursement rate of $0.58/mile), and
laboratory testing (20).
Costs for laboratory tests performed by the APN, activity supplies, and training materials were obtained from
project accounting records.
Wage rates for all personnel were obtained from U.S.
Bureau of Labor Statistics (BLS) occupational data (21)
and were inflated by 31.3% to account for fringe benefits
(22). Personnel time costs were then inflated from $US
2015 to $US 2019 (the most recent year of inflation data
available) (17).
Univariate sensitivity analyses were conducted on
COPE intervention costs to identify ways to deliver the
program more efficiently. The cost of formal staff training
was examined at $0, consistent with a scenario where
interventionists were already trained to deliver COPE.
Telephone calls outside of the COPE (eg, appointment reminder calls or connecting with other community resources)
were omitted under the assumption that they could be converted to less costly and asynchronous forms of communication (eg, e-mails or text messages). Round-trip travel time
was capped at 40 minutes and round-trip travel miles were
capped to 20 miles, simulating a smaller geographic service
area. The cost of interventionist debriefing was tested at
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OT worked with the caregiver to develop solutions for up
to 3 key concerns identified by the caregiver. The OT also
offered strategies to the caregiver to prevent falls in the
home, which in persons living with dementia are a leading
cause of hospitalizations (15), along with strategies to optimize physical activity and activity engagement. During the
APN visit, the person living with dementia received a physical examination and routine blood and urine analyses.
The APN also conducted a medication review as part of
the home visit to check for polypharmacy-related concerns,
explain any potential concerns to the caregiver, and discuss with the caregiver how to raise medication-related issues with the physician of the person living with dementia.
Additionally, the APN provided education for the caregiver
about how to check the person living with dementia for
signs of dehydration, unexpressed pain, constipation, and
signs of infections. The purpose of the APN component
was to identify any underlying medical concerns that could
contribute to functional challenges or behavioral and psychological symptoms. The APN communicated laboratory
results during a follow-up telephone call to the caregiver
(and, if requested by the caregiver, directly to the person
living with dementia’s primary medical provider). The
study was approved by the University of Connecticut institutional review board, inclusive of the trial and cost study
reported herein.
Persons living with dementia and caregiver outcomes
were assessed over 4 months by interviewers who remained
masked to group allocation. Persons living with dementia
outcomes included level of functional dependence, behavioral and psychological symptoms, engagement in
activities, and quality of life (11). Caregiver outcomes
included perceived well-being, self-confidence in using
strategies to manage dementia, and level of distress due
to the person living with dementia’s behavioral and psychological symptoms (11). Trial results showed caregivers
reported better perceived well-being after 4 months of
COPE compared to caregivers receiving usual care. After
12 months of COPE, the persons living with dementia were
more engaged in meaningful activities compared to those
receiving usual care (11).
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half its base case cost, as would be the case if OTs were already proficient with COPE. Finally, the minimum cost to
deliver COPE was calculated by varying all COPE program
components to their low ends simultaneously.

Health care utilization was obtained from the CCC database (informed through monthly check-in calls with the
person living with dementia and/or caregivers by the CCC
care manager) or caregiver interviews (Supplementary
Table A2) for the following categories: nursing home stays
(including long-term and rehabilitation stays), respite care,
inpatient hospitalizations, emergency department, outpatient visits, medications, durable medical equipment, nurse
visits, and home health aide (HHA) visits. The battery used
for capturing this information was developed based on
validated survey instruments (23,24).
Nursing home length of stay was calculated from dates
available in CCC data. Long-term stays were costed by
multiplying the number of days in the nursing home by
published daily rates for each facility (25). Rehabilitation
stays were costed using the FY2015 unadjusted federal perdiem rate for urban facilities (26).
For inpatient hospitalizations and emergency department visits, International Classification of Disease-9/10
diagnosis codes in CCC data were used to estimate mean
charges for that diagnosis per HCUPnet (27), downward
adjusted to approximate health care costs assuming a costto-charge ratio of 1/3.4 (28).
Outpatient visits were recorded during the caregiver
study assessments (visits to primary care physicians,
geriatricians, neurologists, psychiatrists, psychologists,
physical therapists, OTs, and speech language pathologists).
For each visit type, costs were estimated by multiplying the
number of visits by the 50th percentile current procedural
terminology costs per the 2015 National Fee Analyzer (29),
inflated to $US 2019 (Supplementary Table A3) (17).
Visiting nurse and HHA services were also captured
from the caregiver study assessments and were assumed to
be 30 minutes for visiting nurse and 1 hour for HHA.
Medication data in CCC included drug name, strength,
dosage, frequency, and date(s) that the CCC care manager
recorded the medication. For medication entries missing
dosage, strength, or frequency, a seasoned pharmacist applied standard regimens based on product prescribing information (11). Costs were estimated by multiplying the
number of doses by per-dose wholesale acquisition costs
as found in the published databases (30,31). Durable medical equipment, recorded in the CCC data, was costed by
applying reimbursement values (32).
Respite care stays were recorded in caregiver study
assessments and were specified as overnight care. Based on
the services that a respite care facility typically provides, a
proxy cost for respite care days was calculated as 8 hours
of HHA time per day spent in the respite care facility, plus
fringe benefits (21,22).

Caregivers reported the person living with dementia’s visits
from social workers, meals delivered, transportation (to
reach any form of necessity such as medical visits, grocery shopping, etc.), and visits to an adult day care center.
Social worker visits were costed by assuming each visit was
1 hour, and applying the mean Connecticut social worker
wage rate in 2015 ($31.09/h) and fringe benefits rate,
then inflating to $US 2019 (17,21,22). Meals were costed
by applying a per-meal cost of $11.92 to the number of
delivered meals received by the person living with dementia
(33). Transportation costs were based on the senior bus
fare of $1.50 per round trip in $US 2015 and inflated to
$US 2019, applied to the number of round trips taken by
the person living with dementia. Adult day care services
were based on an hourly rate of $12.80 (in $US 2019), and
assuming 8 h/day for each day of service reported (34).

Caregiver Time Costs
Caregivers reported the weekly hours they spent supervising
and assisting the person living with dementia with activities
of daily living and instrumental activities of daily living.
We capped caregiving time to 16 h/day based on references
from published literature (35–37). If the caregiver was currently employed, their time was costed by mapping their
reported occupation to standard BLS occupational wages
plus fringe benefits in $US 2015, then inflating to $US 2019
(17,21,22). If the caregiver was not employed or if their
occupation was missing, the time was costed assuming a
HHA wage rate plus fringe benefits (17,21,22).

Net Financial Benefit
For each cost type, mean per-dyad cost differences from baseline to 12 months were calculated by group assignment and
were compared between groups via a series of 18 familywise
Wilcoxon Rank-Sum tests using the Bonferroni-corrected
significance threshold of α adjusted = .05/18 = .00278.

Assessment of Potential COPE Financing Through
the Connecticut HCBS Program
To assess whether COPE’s intervention costs fit in the
context of CHCPE spending limits, we calculated the percentage of total CHCPE available benefits that would be
required to pay for COPE over 12 months, accounting
for concurrent CM services and considering that the program itself would be delivered for only 4 months out of
the benefit year. Care plan limits were obtained from the
Connecticut Department of Social Services for the CHCPE
categories (13). We conducted this assessment only for
CHCPE Categories 2 and 3 because the trial revealed these
categories were most common in the population of interest
for COPE (over 99% of trial sample population). A flat
40% overhead was added to our COPE intervention costs
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debriefing, OT and APN mileage for travel to participant’s
home, and work outside of COPE delivery. If maximum efficiency is simultaneously achieved for all these categories,
COPE’s intervention costs would be $1 522 per dyad.

%Utilized by COPE/year =

Health Care Service Costs

Care plan limits/month × 12 months
((COPE + overhead costs) × 4 months) + (CM costs/month × 12 months)

Note that CM refers to care management services outside
of COPE, which would be necessary to continue in this
population. A conceptual illustration of the payment model
is provided in Figure A2.

Assessment of Caregiver’s WTP for COPE in
the Context of Connecticut HCBS Program
Cost Sharing
We assessed caregivers’ WTP for COPE at 12 months using
a contingent valuation method. The purpose of capturing
WTP was to understand the monetary value that caregivers
placed on COPE after receiving the program, which in
turn is useful to consider potential cost-sharing amounts.
WTP response options ranged from $0 to $200 per COPE
session.

Results
Demographics for the cost sample population are in Table
1. The majority of persons living with dementia were in
CHCPE Categories 2 (n = 75; 30%) or 3 (n = 172; 68.8%).
Caregivers and persons living with dementia mean ages
were 62.5 (SD 10.9) and 85.2 years (SD 7.9), respectively.
Both caregivers and persons living with dementia were predominantly female (71.6% of caregivers and 76.0% of persons living with dementia). A majority of persons living with
dementia were Caucasian (n = 189; 75.6%), followed by
Black (n = 46; 18.4%) and other ethnicities (n = 15; 6.0%).
In examining costs, the total per-dyad mean cost
differences at 12 months were −$2 354 for COPE and
$4 313 for usual care, yielding a mean DID of −$6 667
(95% CI: −$15 473, $2 734), representing a cost saving for
COPE (Table 2). Utilization of these services (without conversion to $USD) is provided in Supplementary Table A4.

When examining costs for health care services in both
cohorts, the COPE group had a mean per-dyad DID of
−$8 867 (95% CI: −$18 105, $370.81), representing a cost
saving for COPE. These mean per-dyad DID savings were
driven by emergency department use (−$739.76 COPE
vs $2 157 usual care; net −$2 897 [95% CI: −$5 771,
−$23.55]), inpatient hospitalizations (−$470.94 in COPE
vs $2 254 in usual care; net −$2 725 [95% CI: −$6 246,
$795]), and nursing home stays ($3 672 vs $5 334 in COPE
and usual care, respectively; net −$1 662 [95% CI: −$6 258,
$2 934]). These differences were not statistically significant.

Formal Care and Social Services Costs
For costs due to formal care and social services, both
cohorts were observed to have savings in HHA costs,
meals, and adult day care at 12 months compared to baseline; however, all the DID values were modest and not statistically significant.

Caregiver Time Costs
For caregiver time, COPE and usual care experienced mean
costs of −$1 733 and −$1 888 respectively, yielding a mean
per-dyad DID of $154.32 (95% CI: −$1 210, $1 391).

Assessment of Potential COPE Financing Through
the Connecticut HCBS Program
The extent to which COPE would consume CHCPE
spending limits is shown in Table 3. The yearly cost for
COPE plus home health agency overhead and ongoing
CM services is $4 254 regardless of CHCPE category.
Considering the annual CHCPE spending limits of $37 716
($3 143 for 12 months) for Category 2 and $75 432
($6 286 for 12 months) for Category 3 (13), COPE (plus
overhead and ongoing CM) would consume only 11.3% of
the annual spending limit for Category 2 and 5.6% of the
annual spending limit for Category 3.

Intervention Costs
COPE intervention costs were $2 047 (mean total per dyad).
OT/APN time with the dyad was the costliest component
($677.48), followed by travel time ($402.79), laboratory
testing ($340.97), and formal staff training ($218.75).
Sensitivity analyses on COPE intervention costs (Figure
1) revealed that the following, in order of impact, led to the
largest reductions in overall intervention costs: reducing
staff training time, OT and APN travel time, OT and APN

Assessment of Caregiver’s WTP for COPE in
the Context of Connecticut HCBS Program
Cost Sharing
At 12 months, caregivers’ median WTP for COPE was
$50 per session with 84% of CHCPE Category 2 and
75% of Category 3 caregivers willing to pay at least
$25 per session (Supplementary Table A5). These
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to reflect recent data on general administrative costs for
home care agencies (38). The goal of this analysis was to
calculate the percentage of CHCPE care plan funds that
would be required to pay for COPE over a 12-month benefit year, with the equation shown below:
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Table 1. Cost Sample Demographics, Overall and by Group

Characteristic

Overall
N = 250a

Usual Care
n = 120a

2 (1.5%)
38 (29.2%)
90 (69.2%)
62.1 (11.25)
85.1 (8.31)

1 (0.8%)
37 (30.8%)
82 (68.3%)
63.0 (10.58)
85.4 (7.50)

103 (79.2%)
27 (20.8%)

76 (63.3%)
44 (36.7%)

96 (73.8%)
34 (26.2%)

94 (78.3%)
26 (21.7%)

95 (73.1%)
27 (20.8%)
6 (4.6%)
2 (1.5%)
0 (0.0%)

94 (78.3%)
19 (15.8%)
6 (5.0%)
0 (0.0%)
1 (0.8%)

98 (75.4%)
25 (19.2%)
7 (5.4%)
0 (0.0%)
0 (0.0%)

94 (78.3%)
19 (15.8%)
6 (5.0%)
1 (0.8%)
0 (0.0%)

66 (50.8%)
31 (23.8%)
32 (24.6%)
1 (0.8%)

50 (41.7%)
41 (34.2%)
29 (24.2%)
0 (0.0%)

73 (56.2%)
34 (26.2%)
23 (17.7%)

66 (55.0%)
37 (30.8%)
17 (14.2%)

64 (49.2%)
48 (36.9%)
18 (13.8%)

56 (46.7%)
51 (42.5%)
13 (10.8%)

67 (51.5%)
33 (25.4%)
20 (15.4%)
9 (6.9%)
1 (0.8%)

49 (40.8%)
34 (28.3%)
25 (20.8%)
12 (10.0%)
0 (0.0%)

74 (56.9%)
24 (18.5%)
25 (19.2%)
7 (5.4%)

73 (60.8%)
20 (16.7%)
17 (14.2%)
10 (8.3%)

78 (60.0%)
23 (17.7%)
14 (10.8%)
15 (11.5%)

62 (51.7%)
21 (17.5%)
26 (21.7%)
11 (9.2%)

75 (57.7%)
55 (42.3%)

68 (56.7%)
52 (43.3%)

p Valueb
.957

.4889
.7412
.0074

.4597

.4618

.7543

.1909

.6108

.5996

.3392

.5830

.1268

.8987

Notes: CHCPE = Connecticut Home Care Program for Elders; COPE = Care of Persons with Dementia in their Environments; HS = high school.
a
Statistics presented: mean (SD) or n (%).
b
Statistical tests performed: two-sided t test and Fisher’s exact test. All tests were performed at the alpha = 0.05 level.
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CHCPE category
1
3 (1.2%)
2
75 (30.0%)
3
172 (68.8%)
Caregiver age, mean (SD)
62.5 (10.92)
Person living with dementia age, mean (SD)
85.2 (7.92)
Caregiver gender
Female
179 (71.6%)
Male
71 (28.4%)
Person living with dementia gender
Female
190 (76.0%)
Male
60 (24.0%)
Caregiver race
White, Caucasian
189 (75.6%)
Black, African-American
46 (18.4%)
Other
12 (4.8%)
Native American or Alaska native
2 (0.8%)
Unknown/no response
1 (0.4%)
Person living with dementia race
White, Caucasian
192 (76.8%)
Black, African-American
44 (17.6%)
Other
13 (5.2%)
Native American or Alaska native
1 (0.4%)
Unknown/no response
0 (0.0%)
Caregiver highest education attained
College/postgraduate
116 (46.4%)
HS or less
72 (28.8%)
Some college
61 (24.4%)
Unknown/no response
1 (0.4%)
Person living with dementia highest education attained
HS graduate
139 (55.6%)
Less than HS
71 (28.4%)
College/postgraduate
40 (16.0%)
Caregiver employment status
Not working
120 (48.0%)
Full time (>35 h/week)
99 (39.6%)
Part-time (<35 h/week)
31 (12.4%)
Caregiver difficulty paying for the basics
Not difficult at all
116 (46.4%)
Somewhat difficult
67 (26.8%)
Not very difficult
45 (18.0%)
Very difficult
21 (8.4%)
Unknown/no response
1 (0.4%)
Caregiver marital status
Married or living as married
147 (58.8%)
Divorced/separated
44 (17.6%)
Never married
42 (16.8%)
Widowed, not currently married
17 (6.8%)
Caregiver relationship to person living with dementia
Daughter
140 (56.0%)
Spouse
44 (17.6%)
Son
40 (16.0%)
Other
26 (10.4%)
Caregiver and person living with dementia living arrangement
Live together
143 (57.2%)
Live apart
107 (42.8%)

COPE
n = 130a

44.01
36.05
4.01
259.11

7.79
56.50
3.36
280.37

3 361

6 695
74.71
6 077
4 089
1 731
10 407
69.59
23.25
341.74

3 023
98.05
6 548
4 829
239.96
16 827
148.97
45.87
411.48

5 094

218.75
3.87
677.48
59.79
402.79
170.63
177.43
60.34
340.97
1 297

0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
1 362

−1 733
−1 733
−2 354

36.23
−20.45
0.65
−21.26
−4.84

3 672
−23.34
−470.94
−739.76
1 491
−6 420
−79.38
−22.62
−67.40
−2 663

218.75
3.87
677.48
59.79
402.79
170.63
177.43
60.34
340.97
−64.91
2 047

M12–BL

5 256

4.03
39.16
3.63
330.19

1 334
37.94
6 091
4 104
255.08
18 192
175.68
32.90
456.37

0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
1 277

3 368

45.48
31.40
3.94
292.64

6 668
25.30
8 345
6 261
1 880
13 240
79.56
28.59
355.52

0.00
3.87
0.00
0.00
0.00
0.00
0.00
0.14
0.00
1 274

M12

−1 888
−1 888
4 313

41.45
−7.75
0.31
−37.55
−3.55

5 334
−12.64
2 254
2 157
1 625
−4 952
−96.12
−4.31
−100.85
6 204

0.00
3.87
0.00
0.00
0.00
0.00
0.00
0.14
0.00
−3.70
0.30

M12–BL

BL

M12

BL

154.32 (−1 210 to 1 391)
154.32 (−1 210 to 1 391)
−6 667 (−15 473 to 2 734)

.27
.27
.27

.64
1.00
.63
.53
1.00

.47
.37
.12
.08
.38
.28
.96
.10
.43
.04

−1 662 (−6 258 to 2 934)
−10.70 (−243.91 to 215.43
−2 725 (−6 246 to 795.25)
−2 897 (−5 771 to −23.55)
−133.93 (−1 440 to 326.16)
−1 467 (−5 745 to 2 810)
16.74 (−104.18 to 137.66)
−18.31 (−31.94 to 2.50)
31.11 (−63.55 to 78.10)
−8 867 (−18 105 to 370.81)
−5.22 (−47.02 to 18.96)
−12.70 (−26.21 to 27.01)
0.34 (−2.28 to 3.80)
16.28 (−115.74 to 155.44)
−1.29 (−215.62 to 97.02)

—
—
—
—
—
—
—
—
—
.70
.70

p Valuea

218.75
0.00
677.48
59.79
402.79
170.63
177.43
60.21
340.97
−61.21 (−172.98 to 50.54)
2 047

DID (95% CI)
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Notes: ADL = activities of daily living; APN = advanced practice nurse; BL = baseline; CI = confidence interval; COPE = Care of Persons with Dementia in their Environments; DID = difference-in-difference; ED = emergency
department; IADL = instrumental activities of daily living; M12 = month 12; OT = occupational therapist.
a
Statistical test performed: two-sided Wilcoxon rank-sum test.

Direct costs: delivery of intervention or usual care control
Formal staff training
 Screening for program eligibility
 OT/APN time with client
 OT/APN work outside of intervention
 Travel time to participant homes
 Mileage for travel to participant homes
Interventionist debriefing
 Activity supplies and assessment materials
Laboratory testing
Care plan
Subtotal
Direct costs: health care service
Nursing home stays
Respite care
Inpatient hospitalizations
ED visits
Outpatient visits
Medications
 Durable medical equipment
Visiting nurse
Home health aide
Subtotal
Direct costs: formal care and social services
Social worker
Meals
Transportation
Adult day care
Subtotal
Indirect costs: caregiver time
 Supervision/assistance with ADLs and IADLs
Subtotal
Total per-subject mean cost DID

Cost Type

Usual Care Control (n = 120)

COPE Intervention (n = 130)

Table 2. Mean per-Dyad Direct and Indirect Costs for the COPE Intervention vs Usual Care
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Table 3. Percent of CHCPE Care Plan Funds Utilized by COPE

CHCPE
Category

Care Plan
Limits/Month

COPE Cost/
Month

COPE + Administration
Cost/Month

CM Cost/
Month

COPE + Administration
Cost/Year + CM/Year

% Consumed
by COPE

2
3

$3 143
$6 286

$528.01
$528.01

$739.22
$739.22

$108.10
$108.10

$4 254
$4 254

11.28%
5.64%

Note: CHCPE = Connecticut Home Care Program for Elders; COPE = Care of Persons with Dementia in their Environments; CM = care management.

categories have 9% and 0% cost sharing, respectively.
For CHCPE Category 2, assuming that the maximum
amount spent towards the cost share is 9% of the
$3 143 monthly total spending limit ($282.87) and the
participant receives a maximum of 3 COPE sessions
per month and pays a $25 per session copayment ($75
total), COPE cost sharing would be well below the maximum possible cost sharing borne by participants for
the 4 months of the program. For CHCPE Category 3,
participants have 0% cost sharing and thus we assumed
caregivers would not need to be willing to pay anything
for COPE. Therefore, cost sharing for COPE through
the Connecticut HCBS program may represent a feasible payment mechanism and would foster sustainability of this intervention.

Discussion and Implications
The COPE-CT pragmatic trial demonstrated that the COPE
intervention can be successfully implemented through
Connecticut HCBS. Our CBA revealed that COPE intervention costs also fall within existing CHCPE spending
limits, accounting for ongoing CM services to this population, even without consideration of the potential cost savings with COPE. A major strength of our analysis is that we

used a CM organization’s data linked to trial data to obtain
a robust array of cost measures.
COPE itself costs more than $2 000 per dyad (>$500
per month) above and beyond usual care, but efficiencies
in training and delivery could reduce this figure to approximately $1 500. Importantly, however, our CBA suggests
potential savings in direct health care costs by COPE
participants. Most notably, our findings suggest that COPE
participants experienced cost savings in nursing home
stays, emergency room use, inpatient hospitalizations, and
medications. We postulate that the home support provided
by COPE better equipped caregivers to manage dementia,
which in turn enabled them to better navigate the care
system. Generalized linear models from the main trial analysis indicate improvements in both the person living with
dementia’s behavioral and psychological symptoms score
as well as the caregiver’s own perceived well-being (11).
As recommended by the 2018 National Research
Summit on Care, Services, and Supports for Persons with
Dementia and Their Caregivers, efficacious programs that
demonstrate positive outcomes for persons living with
dementia and their caregivers also need viable payment
models to support scaling, dissemination, and sustainability (6). In this study, we tested embedding the COPE
program into Connecticut HCBS. Considering that COPE
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Figure 1. Univariate sensitivity analyses of COPE intervention costs.
Note: APN = advanced practice nurse; COPE = Care of Persons with Dementia in their Environments; OT = occupational therapist.
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course of their 12 months in the study. While this study cohort may not be representative of all community-dwelling
persons living with dementia, they might be more representative of persons living with dementia enrolled in Medicaid
waiver and state-funded HCBS programs in other states that
target those at risk or eligible for nursing home entry. Second,
the study was powered on the main outcomes for the parent
trial but not on the cost study, and we were unable to detect
statistical significance between the groups. This is common
for cost assessments conducted alongside clinical trials (45).
Third, information regarding health care resource utilization was obtained either from the CCC database (informed
through biannual interviews of the caregiver by the CCC care
manager) or through study interviews, as claims data were
not available for this analysis. Fourth, the WTP question only
asked about willingness to pay, without considering ability
to pay. Thus, the WTP reported does not necessarily equate
to a financial ability to pay; however, it should be noted that
the per-session WTP reported are modest and likely achievable for many dyads. Finally, we assessed possible financing
of COPE through Connecticut HCBS only, but the concept
may be replicable in other states’ HCBS programs depending
on their eligibility criteria and spending thresholds. Further
research is needed to understand how COPE may be afforded
through other state HCBS programs.
The COPE program trended toward net cost savings in
several direct health care cost categories including emergency department visits, inpatient hospitalizations, and
medications, and can be afforded by the Connecticut
CHCPE based on current monthly cost caps and costsharing percentages. State- and Medicaid-funded HCBS
programs represent an important, sustainable payment
model for delivering nonpharmacological dementia
interventions such as COPE.

Supplementary Material
Supplementary data are available at Innovation in Aging online.
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only utilizes 5.6%–11.3% of the yearly CHCPE care plan
limits, COPE could likely be covered through this program.
Though HCBS programs vary from state to state in terms
of eligibility, spending limits, and covered services, our
findings from Connecticut provide a proof-of-concept that
warrants consideration by other states.
Another option for a payment model would be through
Medicare. Boustani et al. (39) have recently recommended
that the Centers for Medicare and Medicaid Services provide
a per beneficiary per month payment to cover comprehensive
dementia care using collaborative dementia care models for
the person living with dementia and support and education
for their unpaid caregivers. The Alzheimer’s Association and
the Alzheimer’s Impact Movement also published a Medicarebased alternate payment model proposal, with key elements
including a capitated and performance based payment structure (40). Overall, some key conditions for sustainable payment for COPE under Medicare would require that visits
by the OT and APN be covered in type and number, specific
billing codes be established for the services, costs for COPE to
not exceed benefit and or reimbursement caps, the 12 COPE
visits (10 OT, 2 APN) be recognized as a “package” to avoid
rejections and interruptions, and for COPE to be authorized
by appropriate personnel. Of note, the new Medicare ADRD
care planning service codes are not sufficient for the COPE
program (41). As these payment approaches evolve, it is becoming apparent that there will not be a single payment model
suitable for all dementia nonpharmaceutical interventions.
There are very few published economic analyses
examining dementia care programs that support both persons living with dementia and caregivers. In a study assessing
the cost–benefit of 10 sessions of OT at home over 5 weeks
versus usual care in persons living with dementia and caregiver dyads, the intervention group achieved a cost savings
of €1 748 ($2 737, 2019 USD) in total care costs, though
this was nonsignificant (42). This difference was driven by
reduction of informal care costs (care given by offspring,
neighbors), nursing home costs, and hospitalization costs
(42). In another pilot program that examined the impact
of a care coordination and support partnership between a
telephonic nursing program and a home care organization
in Alzheimer’s patients and caregiver dyads, the intervention group had lower average inpatient costs compared
to the historical control group, at $12 989 and $30 650,
respectively (p < .011) (43). However, the use of a historical control group makes it difficult to discern the actual
impact of the intervention. With respect to WTP, a study
assessing caregiver WTP for a similar in-home intervention
to help manage behavioral symptoms and caregiver stress
indicated that the mean adjusted WTP at baseline was $36
per session (44), which is similar to WTP values for COPE.
The study has several limitations. First, the person living
with dementia in this study may have been more advanced
in their disease than in other populations of communitydwelling persons living with dementia, as evidenced by the
increase in nursing home costs for both groups over the
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